Rafael Gonzalez, Ph.D., brings to Gentera his extensive background in degenerative disorders involving the spinal cord, as well as stem cell culture and biology from human embryonic, perinatal, and adult sources. Through his comprehensive research pursuits, he pushes the boundaries of science while remaining mindful to his staunch code of ethics and standards.
Gentera’s Senior Scientific Advisor and Board Member began his academic career at the University of California Irvine, earning his bachelor of science degree in Biological Science and a doctorate in Neurobiology. While earning his Ph.D., Dr. Gonzalez led preclinical studies, leading to the startup Ability Biomedical, which developed an anti-P 10 antibody to treat several degenerative disorders, including multiple sclerosis, rheumatoid arthritis, and spinal cord injury. The startup has since been acquired by Bristol-Myers Squibb.
As a Research Scientist at PrimeGen Biotech, Dr. Gonzalez was responsible for developing PrimeGen’s preclinical stem cell/spinal cord injury model.